L3VLUP
ProSign in

KYMR in the 13F filings

Kymera Therapeutics Inc · CUSIP 501575104

Sector · Pharmaceuticals and biotechnologyTheme · Biological productsTheme · Healthcare: biopharma and medtech· L3VLUP-defined
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Quarter end
30 Sep 2023
the date the book describes
Filed
14 Nov 2023
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q2 2023 and Q3 2023; 1 listed it in both
Shares listed
103,189
combined, among listed positions
Reported value
$1.4m
combined, at the quarter end

Managers listing KYMR in Q3 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Woodline Partners LP103,189$1.4munder 0.1%Trimmed-5,59214 Nov 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
5 in Q3 2024 to 8 in Q2 2026

Tracked managers listing it, at least.

0246820222023202420252026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
KYMR by quarter
QuarterHoldersReported valueBuyersSellers
Q3 20202$8.3mn.a.n.a.
Q4 20201$11mn.a.n.a.
Q2 20211$1.8mn.a.n.a.
Q3 20211$7.6mn.a.n.a.
Q4 20211$171mn.a.n.a.
Q1 20222$30mn.a.n.a.
Q2 20221$2.0mn.a.n.a.
Q3 20221$2.2mn.a.n.a.
Q4 20223$226mn.a.n.a.
Q1 20233$268mn.a.n.a.
Q2 20231$2.5mn.a.n.a.
Q3 20231$1.4mn.a.n.a.
Q4 20233$150m21
Q1 20246$496m42
Q2 20244$343m31
Q3 20245$582m32
Q4 20246$536m51
Q1 20254$372m23
Q2 20255$615m32
Q3 20256$737m23
Q4 20257$1.7bn1512
Q1 20268$2.1bn1215
Q2 20268$3.0bn1213

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

KYMR and GILD →KYMR and AMGN →KYMR and ARGX →Choose a stock to compare with KYMR →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own KYMR, latest filings →Back to the 13F Explorer →